This announcement is a separate document:
アステラス製薬：欧州委員会、進行性尿路上皮がんの第一選択治療薬としてアステラスのPADCEVとKEYTRUDAの併用を承認
Astellas Pharma: European Commission Approves Astellas’ PADCEV in Combination with KEYTRUDA for First-Line Treatment of Advanced Urothelial Cancer
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.